CADTH | Evidence Driven
CADTH | Evidence Driven

Midostaurin (Rydapt) for Systemic Mastocytosis

Details

Files
Generic Name:
Midostaurin
Project Status:
Complete
Therapeutic Area:
Systemic Mastocytosis
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Rydapt
Project Line:
Reimbursement Review
Project Number:
PC0193-000
NOC Status at Filing:
Post NOC
Strength:
25 mg
Tumour Type:
Other
Indications:
Systemic Mastocytosis
Funding Request:
For the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
Sponsor:
Novartis Pharmaceuticals Canada Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Midostaurin (Rydapt) Systemic Mastocytosis – pERC Final Recommendation Final Recommendation April 2, 2020 View PDF
Midostaurin (Rydapt) Systemic Mastocytosis – Final Economic Guidance Report Guidance Reports April 2, 2020 View PDF
Midostaurin (Rydapt) Systemic Mastocytosis – Final Clinical Guidance Report Guidance Report April 2, 2020 View PDF
Midostaurin (Rydapt) Systemic Mastocytosis – pERC Initial Recommendation Initial Recommendation January 30, 2020 View PDF
Midostaurin (Rydapt) Systemic Mastocytosis – PAG Feedback on Initial Recommendation Feedback April 2, 2020 View PDF
Midostaurin (Rydapt) Systemic Mastocytosis – Manufacturer Feedback on Initial Recommendation Feedback April 2, 2020 View PDF
Midostaurin (Rydapt) Systemic Mastocytosis – Patient Advocacy Group Feedback on Initial Recommendation Feedback April 2, 2020 View PDF
Midostaurin (Rydapt) Systemic Mastocytosis – Clinician Feedback on Initial Feedback April 2, 2020 View PDF
Midostaurin (Rydapt) Systemic Mastocytosis – Patient Advocacy Group COI Declarations COI Declarations April 2, 2020 View PDF
Midostaurin (Rydapt) Systemic Mastocytosis – Clinician COI Declarations COI Declarations April 2, 2020 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : April 20, 2020